For both new and experienced investors, maximizing the potential of the stock market and investing with confidence are common objectives. One way to achieve these goals is by utilizing the Zacks Style Scores, a unique tool that evaluates stocks based on popular investing strategies such as value, growth, and momentum. These scores can help investors identify which stocks are suitable for their portfolios and have the potential to outperform the market in the long run.
When it comes to growth investing, investors focus on companies that are financially robust and poised for future growth. The Growth Style Score considers factors such as projected and historical earnings, sales, and cash flow to pinpoint stocks with sustainable long-term growth potential.
One stock that stands out for growth investors is United Therapeutics (UTHR), a company based in Silver Spring, MD. United Therapeutics markets medications in the United States to treat pulmonary arterial hypertension (PAH), including Remodulin, Orenitram, Tyvaso, and Adcirca. With a Growth Style Score of A and a VGM Score of A, United Therapeutics holds a Zacks Rank #3 (Hold) rating. Analysts anticipate a 24.3% year-over-year increase in its bottom line for 2024, along with a 16.7% improvement in its top line.
In the past 60 days, eight analysts have raised their earnings estimates for United Therapeutics, leading to a Zacks Consensus Estimate of $24.62 per share for 2024, up $1.16 from previous estimates. The company has a history of delivering earnings surprises, with an average surprise of 12.4%. Additionally, United Therapeutics has shown strong cash flow growth, with a 10.7% increase historically and a projected 33.3% expansion for the current year.
With its solid fundamentals, favorable Zacks Rank, and top-notch Growth and VGM Style Scores, United Therapeutics is a stock worth considering for investors. If you’re interested in receiving more stock recommendations from Zacks Investment Research, download their free report on the 7 Best Stocks for the Next 30 Days.